These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 24122718

  • 21. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
    Spitthöver R, Röseler T, Julius U, Heigl F, Schettler VJJ, Kühn R, Leebmann J, Raabe A, Knittel M, Schürfeld C, Moesenthin M, Bernhardt WM, Röseler E, Ketteler M, Heibges A, Klingel R.
    J Clin Apher; 2019 Aug; 34(4):423-433. PubMed ID: 30817043
    [Abstract] [Full Text] [Related]

  • 22. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.
    Circulation; 2015 Oct 27; 132(17):1648-66. PubMed ID: 26503748
    [Abstract] [Full Text] [Related]

  • 23. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 27; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 24. A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.
    Lin J, Wang LY, Liu S, Wang XM, Yong Q, Yang Y, DU LP, Pan XD, Wang X, Jiang ZS.
    Chin Med J (Engl); 2010 May 05; 123(9):1133-8. PubMed ID: 20529551
    [Abstract] [Full Text] [Related]

  • 25. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
    Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.
    Nutr Metab Cardiovasc Dis; 2013 Nov 05; 23(11):1115-21. PubMed ID: 23333725
    [Abstract] [Full Text] [Related]

  • 26. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan 05; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 27. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N.
    Eur J Prev Cardiol; 2018 Nov 05; 25(17):1843-1851. PubMed ID: 30058841
    [Abstract] [Full Text] [Related]

  • 28. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A, Levoye A, Lambert G, Louedec L, Journé C, Meilhac O, Amarenco P.
    Stroke; 2014 Oct 05; 45(10):3086-8. PubMed ID: 25123222
    [Abstract] [Full Text] [Related]

  • 29. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ, Muellendorff F, Schettler E, Platzer C, Norkauer S, Julius U, Neumann CL.
    Ther Apher Dial; 2019 Oct 05; 23(5):467-473. PubMed ID: 30663261
    [Abstract] [Full Text] [Related]

  • 30. [Position of lipoprotein apheresis in present].
    Bláha V, Bláha M, Lánská M, Havel E, Vyroubal P, Zadák Z, Vrablík M, Piťha J, Žák P, Sobotka L.
    Vnitr Lek; 2015 Nov 05; 61(11):958-64. PubMed ID: 26652784
    [Abstract] [Full Text] [Related]

  • 31. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
    Lappegård KT, Kjellmo CA, Ljunggren S, Cederbrant K, Marcusson-Ståhl M, Mathisen M, Karlsson H, Hovland A.
    Transfus Apher Sci; 2018 Feb 05; 57(1):91-96. PubMed ID: 29398508
    [Abstract] [Full Text] [Related]

  • 32. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.
    Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M.
    Arterioscler Thromb Vasc Biol; 2004 Aug 05; 24(8):1448-53. PubMed ID: 15166014
    [Abstract] [Full Text] [Related]

  • 33. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI, Ezhov MV, Razova OA, Afanasieva MI, Utkina EA, Pokrovsky SN.
    Atherosclerosis; 2018 Oct 05; 277():477-482. PubMed ID: 30270088
    [Abstract] [Full Text] [Related]

  • 34. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
    Davidson MH.
    J Clin Lipidol; 2013 Oct 05; 7(3 Suppl):S11-5. PubMed ID: 23642323
    [Abstract] [Full Text] [Related]

  • 35. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 36. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA, Nohara A, Higashikata T, Tada H, Nakanishi C, Okada H, Konno T, Sakata K, Hayashi K, Inazu A, Mabuchi H, Yamagishi M.
    Atherosclerosis; 2017 Oct 13; 265():225-230. PubMed ID: 28926730
    [Abstract] [Full Text] [Related]

  • 37. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.
    Circulation; 2013 Jun 18; 127(24):2403-13. PubMed ID: 23690465
    [Abstract] [Full Text] [Related]

  • 38. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H, Rashid S, Fazio S.
    Atherosclerosis; 2015 Feb 18; 238(2):264-70. PubMed ID: 25544176
    [Abstract] [Full Text] [Related]

  • 39. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Feb 18; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 40. Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.
    Huijgen R, Fouchier SW, Denoun M, Hutten BA, Vissers MN, Lambert G, Kastelein JJP.
    J Lipid Res; 2012 May 18; 53(5):979-983. PubMed ID: 22375030
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.